In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 39496169.
- Also identified by DOI 10.7326/ANNALS-24-02459-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Usman MS, Bhatt DL, Hameed I, et al. <b>Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.</b> Lancet Diabetes Endocrinol. 2024;12:447-461. 38768620.